Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
about
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapyVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerEvaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleUnderstanding and altering cell tropism of vesicular stomatitis virusLDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virusChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainCutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective ImmunityPotential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting.Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsVesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primatesOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesSafety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic virusesSystemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cellsDifferentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.VSV-tumor selective replication and protein translation.Characterization of resistance to rhabdovirus and retrovirus infection in a human myeloid cell line.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx.Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.Curative one-shot systemic virotherapy in murine myeloma.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell LeukemiaEXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMANeuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Viruses as anticancer drugs.Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes
P2860
Q24605512-79A76559-DC46-4A0F-AA88-44972AF28506Q27021839-D7C7D206-A428-4284-B010-157A5155AC42Q27473287-136BC7F2-AB9E-4FF0-AA6F-E978AA11E0EFQ27687067-FC19D155-99E7-4549-A3CD-204BDE381A57Q28118448-B1D4781F-1D29-41F5-96E1-73C97A69DAF5Q28223031-99026909-26AB-4D5F-803F-512C013BC765Q29365197-E5C2F0DB-4EBB-4C9C-8F97-1C53111AFDAAQ33579385-6F68E314-DDD9-40FA-9421-40639FA4ACE4Q33614368-465D0583-A01C-4A90-ACBB-DD7B7B15183AQ33620680-3077687D-6CDC-44FD-ABC6-9F6E45466964Q33667768-16AC6762-5A5D-4024-A2A9-B2C25C6149C4Q33691838-EEC1E92E-4D61-46CF-A260-47ED2388577EQ33780536-A468394D-6FD4-4073-AB51-711ED9D6FC0DQ33832148-2203B9CC-CCFB-4C1D-B481-6F3EFCB844DFQ33832168-0C11C678-3B07-4CC7-B789-0C3E9EDFB8A6Q33924550-CF02D08E-63FA-42D9-A1F5-EA18BA69F9D7Q34013572-FD9F6045-7730-4F5A-848A-619424287B32Q34092661-726EF334-2CA3-4097-990D-D8B7503F1566Q34110261-DF61C558-69EE-4DAD-A95A-1BF0C2095385Q34371450-83D4929B-C26D-4E4D-8D1E-744D8511F373Q34434660-BD55D6D6-A515-4D54-911A-20B9D7D609C2Q34648125-C273204F-3971-46E3-A2DD-62117A82E461Q34651274-A1BD60E3-6E90-482F-9217-FE2A4E744448Q35219724-FF5E236C-0B0A-44D1-961E-4E2E0762CD2FQ35275179-C308EA32-2888-4C2E-98A5-B1938F76CE5EQ35641491-FB242683-297D-495B-9514-E12A381A88BFQ35784861-1F0CE1C3-A33A-4D15-BD63-B041FBC686F1Q35840314-FADB4F21-203E-4D02-9FA5-82783055592DQ35861186-E25BCF36-D852-4B61-B474-4B63F8661786Q35988675-8EFD6E23-6CBF-4B86-AEC5-5D1A65FFE23EQ36007610-640BE6F7-0A5F-4C63-9331-64B8EAC6649DQ36049446-DFFBC5D5-D108-4B01-88ED-76582C2F67C1Q36139716-39E8D42D-2B21-4C64-98FA-C8BFB1EB3CC8Q36202610-209A2582-A97E-4683-A149-16753B272621Q36281149-A0B4DE05-1D1E-4942-9B8B-AC4DED82751AQ36549443-0C350777-3EB0-40EC-A6FC-0D7102745826Q36667968-20EABC79-C3B9-48E3-9405-0B7E6BFEDBB2Q36751597-D7F3AA63-C29D-4C26-A88C-319B1DBCF1B4Q36850878-F5426043-BA82-49DB-9B58-C564051711DDQ36911654-80ED1A92-290C-4CCB-8C84-25BBD9E9204A
P2860
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development of recombinant ves ...... t specific oncolytic activity.
@ast
Development of recombinant ves ...... t specific oncolytic activity.
@en
type
label
Development of recombinant ves ...... t specific oncolytic activity.
@ast
Development of recombinant ves ...... t specific oncolytic activity.
@en
prefLabel
Development of recombinant ves ...... t specific oncolytic activity.
@ast
Development of recombinant ves ...... t specific oncolytic activity.
@en
P2093
P2860
P1433
P1476
Development of recombinant ves ...... t specific oncolytic activity.
@en
P2093
Glen N Barber
Marilyn Fernandez
Masatsugu Obuchi
P2860
P304
P356
10.1128/JVI.77.16.8843-8856.2003
P407
P577
2003-08-01T00:00:00Z